Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aimaimaitosai
- Development stage
- Unknown
- Lead developer
- Platinumlife Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Aimaimaitosai (Ruibosheng) is a human umbilical cord tissue-derived mesenchymal stem cell (hUC-MSC) therapy developed by Platinumlife Biotech. It is the first mesenchymal stem cell product to receive regulatory approval in China, specifically indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following hematopoietic stem cell transplantation. The therapy exerts its therapeutic effects through complex immunomodulatory mechanisms involving both direct cell-to-cell contact and the paracrine secretion of anti-inflammatory factors such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), and indoleamine 2,3-dioxygenase (IDO). These actions lead to the induction and expansion of regulatory T cells (Tregs) and Th2 anti-inflammatory cells, while simultaneously suppressing the proliferation and activity of Th1 cells and B-cells, thereby restoring immune homeostasis and reducing the systemic inflammation associated with aGVHD.
- Brand names
- Ruibosheng睿铂生
- Other names
- Aimaimaitosai Injection艾米迈托赛注射液Human Umbilical Cord Mesenchymal Stem CellshUC-MSC
02
Targets
PGE2 (Prostaglandin E2)IL-6 (Interleukin 6)IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on aimaimaitosai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aimaimaitosai.